Targeting Senescent Alveolar Type 2 Cells with a Gene-Editable FePt Dual-Atom Catalyst for Mitigating Idiopathic Pulmonary Fibrosis.

Qianglan Lu, Chengwei Ye, Wei Mao, Fei Zeng, Zhiyong Liu, Ruiyue Chen, Xiao Cheng, Yanfeng Gao, Meng Wang, Mei Liu, Shaochun Tang, Yujun Song

Department of Gastric and Hernia Surgery, Nanjing Drum Tower Hospital, College of Engineering and Applied Sciences, State Key Laboratory of Analytical Chemistry for Life Science, Nanjing University, Nanjing 210023, China.Department of Gastric and Hernia Surgery, Nanjing Drum Tower Hospital, College of Engineering and Applied Sciences, State Key Laboratory of Analytical Chemistry for Life Science, Nanjing University, Nanjing 210023, China. · pubmed

Paper

Abstract

Idiopathic pulmonary fibrosis (IPF) remains an age-related, fatal, incurable, epithelial-driven fibrotic lung disease despite the availability of approved antifibrotic drugs. The medical need for effective antipulmonary fibrotic therapies is thus very high. A promising therapeutic intervention for IPF is to target key cellular senescence processes in alveolar type 2 (AT2) cells. Herein, we introduce an inhalable gene-editable nanoplatform, comprising a CRISPR-Cas9 gene-editing system linked to a core FePt diatomic catalyst, encapsulated within a biocompatible hyaluronic acid (HA) surface layer (FePtR@HA). The FePt diatomic site facilitates H

The following analysis is generated by AI and may contain errors. It is separate from the authors’ abstract and is not peer review.

Research summary

The paper claims that an inhalable gene-editable nanoplatform can target senescent alveolar type 2 cells to mitigate idiopathic pulmonary fibrosis. This research addresses a key aspect of cellular senescence, which is a fundamental process associated with aging and age-related diseases, thus contributing to the understanding of potential interventions in longevity.

Author of this paper? Send a correction.